DOCSLIB.ORG

Focus on Treatment Developments in Three Less Commonly Researched Chronic Skin Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Focus on Treatment Developments in Three Less Commonly Researched Chronic Skin Diseases RESEARCH CORNER Focus on treatment developments in three less commonly researched chronic skin diseases Kathy Radley, Senior Lecturer, School of Kathy Radley Life and Medical Sciences, University of Background Hertfordshire, and Project Coordinator, Eczema Education Programme, Guy’s and This quarter’s Research Corner takes a focus on chronic skin disease. In dermatology, St Thomas’ NHS Foundation Trust, reviews when considering the term chronic skin disease, it is often the ‘big three’ that spring recent studies on hidradenitis suppurativa, to mind — eczema, acne and psoriasis. The three studies chosen avoid the ‘big three’ rosacea and vitiligo. and focus on chronic skin diseases which, although common, attract less funding and research: hidradenitis suppurativa (HS), rosacea and vitiligo. HS affects 1% of the European population1, rosacea 1-22%2 and vitiligo 1% worldwide3. These papers all have a valuable role in providing evidence base for the management of these conditions. pain, hidradenitis severity score and duration outcomes graded above low quality of evidence. of remission. 12 RCT studies including 615 Subcutaneous injections with S. aureus lysis participants were included in the review. showed improvement in outcomes graded moderate quality, although this is an old study6 and Key fi ndings has not been repeated since. Many of the 12 studies reviewed had First study methodological fl aws leading to the quality of the Commentary evidence being downgraded. Only 4 trials reported This systematic review has not identifi ed any Citation on outcome of QoL, all reported on adverse trials where the improvement in outcomes led Ingram JR, Woo PN, Chua SL, et al. Interventions effects. Please refer to the systematic review for the to high-quality evidence. The strongest evidence for hidradenitis suppurativa (Review). details of the trials, as the report below is a brief came from the trial indicating the use of weekly Cochrane Database Sys Rev, 2015, Issue 10. summary. The web link to the full review is included dosed adalimumab (double the dose licensed Available at: http://onlinelibrary.wiley.com/ in the citation above and will also give access to the for psoriasis). There is no evidence for the use doi/10.1002/14651858.CD010081.pub2/abstract Cochrane database of systematic reviews. of many oral systemic agents currently used to treat patients with HS. Validity and clinical Context In the pharmacological studies, the trials of meaningfulness of the outcome measures for Hidradenitis suppurativa (HS) is a chronic, anti-TNFα infl iximab dosed at 5mg per kg and HS leads to a lack of clinical trials of a quality for infl ammatory skin condition characterised by adalimumab dosed weekly showed improvements in inclusion in a review such as this. recurrent, painful boils in fl exural sites4. outcomes and rated as moderate quality evidence. Implications The objective of this systematic review is to assess Topical 1% clindamycin solution showed Five ongoing trials considering the effi cacy of the effects of interventions for HS in people of all improvement in outcomes with evidence also biologics in HS have been identifi ed from trial ages. The HS Priority Sharing Partnership in 20135 rated as moderate. Oral ethinyloestradiol and registers but currently there remains little robust identifi ed a gap in evidence for treatment of HS and cyproterone acetate and ethinyloestradiol and evidence for the treatment of HS. this review is a starting point to address these gaps. norgestrel both identifi ed improvements with the evidence-rated moderate. Second study Methods The systematic review included randomised One study reported an improvement in the Citation controlled trials (RCTs) of interventions for HS. patient-reported global assessment looking at Taieb A, Ortonne JP, Ruzicka T, et al. Superiority RCTs were included for any intervention and the oral tetracycline but the evidence is graded low. of ivermectin 1% cream over metronidazole participants required a clinical diagnosis of HS In surgical interventions the use of gentamycin 0.75% cream in treating infl ammatory lesions of made by a medical practitioner. Interventions were sponges versus primary closure alone showed rosacea: a randomised, investigator-blinded trial. Br J grouped into three categories; pharmacological, improvements with the evidence graded as Dermatol 2015, 172: 1103-1110 surgical and other interventions. Primary moderate quality. outcomes measured were quality of life (QoL) Context and adverse effects, with secondary outcomes In the other interventions group, no laser or Rosacea is a relatively common chronic being global assessment by patients and physician, light intervention identifi ed any improvement in infl ammatory skin disease affecting mainly adults, 50 Dermatological Nursing, 2016, Vol 15, No 2 www.bdng.org.uk ResearchCornerJun.jp3C2.indd 54 02/06/2016 17:17 RESEARCH CORNER predominantly women. There are few treatments validity and reliability of the results. to use, with just 7% saying it was diffi cult and none Focus on treatment developments with a good evidence base. Ivermectin is a Topical ivermectin is licenced in the UK as saying very diffi cult. macrocyclic derivative — an anti-parasitic with Soolantra® cream8. anti-infl ammatory properties. This study sought to Commentary in three less commonly researched compare the effi cacy of ivermectin 1% cream once Implications In the absence of an easy-to-use and valid tool daily with metronidazole 0.75% cream twice daily. This study identifi es an evidence-based treatment this study indicates the VNS has good construct option to discuss with patients. Phase 2 validity (the degree to which scores of a given chronic skin diseases Methods (continuing 36-week trial to look at recurrence) of measurement instrument are consistent with This was an investigator-blind, randomised, parallel the study is reported by Taieb et al9. hypotheses), is acceptable to patients to use and group study. It was conducted over a 16-week identifi es good interpretability. Patients were period, which this paper reports on, with a Third study central to the development of the VNS so this further 36-week period following to investigate is not surprising. Additionally the VNS dealt recurrence. Participants over 18 years of age were Citation with issues of hyperpigmentation, which the % recruited by 64 centres in 10 European countries Batchelor JM, Tan W, Tour S, Yong A, Montgomery repigmentation scale does not. The participants with moderate or severe papulopustular rosacea. AA, Thomas KS. Validation of the vitiligo were self-selecting so may not be totally noticeability scale; a patient-reported outcome representative of the patient group as a whole. 962 participants were randomised, 478 in the measure of vitiligo treatment success. Br J Dermatol ivermectin arm and 484 in the metronidazole arm. 2016, 174: 386-394 Implications Outcomes measured were a reduction in lesion This tool is free and easy to use, and could be count, Investigator’s Global Assessment (IGA) and Context utilised in a clinical setting. Crucially it is a patient- patient-reported outcomes (a 5-point global scale, Vitiligo is a chronic skin disease causing reported outcome measure. The VNS can be satisfaction questionnaire and Dermatology Life depigmentation. A large number of RCTs have accessed at www.nottingham.ac.uk/research/ Quality Index (DLQI)). been undertaken and published assessing groups/cebd/projects/2vitiligo/vitiligo-outcome- treatments for vitiligo but the lack of standard measures.aspx and used with permission. Further Key fi ndings outcome measures ensures comparison of validation is required with a larger cohort of 93.8% participants completed the study. Baseline treatment effect is diffi cult. A measure frequently participants and with a wider range of genuine demographics were comparable in both arms of used is an estimation of ≥75% repigmentation (rather than digitally manipulated) pre- and post- the study. At 16 weeks lesion count had reduced but there is no validation of this and patient- treatment images. DN by 83.0% in the ivermectin arm and 73.7% in the reported outcome measures are rarely used metronidazole arm (p<0.001). IGA was reported in vitiligo studies. This paper aims to validate a References as clear or nearly clear with ivermectin 84.9% vs previously developed patient-reported outcome 1. Revuz J. Hidradenitis suppurativa. JEADV 2009, metronidazole 75.4% (p<0.001). Patient-reported measure, the vitiligo noticeability scale (VNS), by 23(9): 985-98 outcomes showed the global rating of excellent asking whether the VNS is a better and more 2. Spoendlin J, Voegel JJ, Jick SS & Meier CR. A study or good for ivermectin 76% and metronidazole consistent indicator of treatment success than % on the epidemiology of rosacea in the UK. Br J Dermatol 74.8%. Satisfaction ranked at 76% for ivermectin vs repigmentation. The VNS is a score of 1-5 with 1 2012, 167(3): 598-605 = more noticeable and 5 = no longer noticeable. 3. Whitton ME, Pinart M, Batchelor J, et al. 61.3% for metronidazole and DLQI reduced by an Interventions for vitiligo. Cochrane Database Syst Rev average of 5.15 in the ivermectin arm, 3.93 in the 2015, 2:CD003263 metronidazole arm. Methods 4. Jemec GB. Clinical practice. Hidradenitis Patient participants were recruited via a mailing suppurativa. New Engl J Med 2012, 366(2): 158-64 Adverse effects reported were mainly skin list, the Vitiligo Society and social media and 5. James Lind Alliance, 2013. Hidradenitis suppurativa irritation at a rate of 0.6% for the ivermectin dermatologists based in the UK who had Priority Sharing Partnership. Available at: www.jla. arm and 0.8% for the metronidazole arm. Three previously expressed an interest. There were 101 nihr.ac.uk/priority-setting-partnerships/hidradenitis- suppurativa [accessed 24.4.16] participants in the ivermectin arm discontinued patient responders and 33 clinicians. 6. Angel MF, Ramasastry SS,Manders EK, Ganfi eld D, treatment and 10 in the metronidazole arm. Pre- and post-treatment digitally manipulated Futrell JW.
Load more

Recommended publications
  • Infectious Eccrine Hidradenitis Associated with Intense Sun Exposure
    Infectious Eccrine Hidradenitis Associated With Intense Sun Exposure Charlotte Hwa Vuong, MD; Ruth Walters, MD; Jennifer A. Stein, MD, PhD Practice Points Neutrophilic eccrine hidradenitis is a response to nonspecific stimuli in a wide spectrum of clinical settings. Infectious eccrine hidradenitis should be included in the differential diagnosis in patients who develop an erythematous papular eruption after sunburn. Infectious eccrine hidradenitis (IEH), which usu- erythematous papules on the flanks, grouped pap- ally manifests as singular or multiple erythema- ules and pustules on the back, and papules on the tous papules or plaques, is a rare dermatosis legs in areas of resolving sunburn (Figure 1). It involving an infectious agent and histologic find- was her first sun exposure of the season, and the ings identical to that of CUTISneutrophilic eccrine patient previously had used the same sunscreen, hidradenitis (NEH). We report a case of IEH in which she applied on all parts of her body. Her cur- a 24-year-old woman who developed a pruritic, rent medications included desogestrel and ethinyl erythematous, papular rash after a sunburn. A estradiol, naratriptan hydrochloride, and loratadine culture of a pustule revealed methicillin-sensitive and pseudoephedrine. Staphylococcus aureus. Our patient had complete Histology showed a superficial and deep peri- resolution of her rash within 2 weeks of starting vascular infiltrate of lymphocytes, histiocytes, and amoxicillinDo and clavulanate. ThisNot case of IEH and neutrophils Copy with prominent neutrophilic infiltration NEH related to both intense sun exposure and of eccrine glands (Figure 2). In the overlying epider- infection supports the hypothesis that NEH is a mis, there was focal parakeratosis with a collection of response to nonspecific stimuli and may occur in neutrophils and an aggregate of gram-positive cocci.
    [Show full text]
  • Endocrinology 12 Michel Faure, Evelyne Drapier-Faure
    Chapter 12 Endocrinology 12 Michel Faure, Evelyne Drapier-Faure Key points 12.1 Introduction Q HS does not generally appear to be In 1986 Mortimer et al. [14] reported that hi- associated with signs of hyperan- dradenitis suppurativa (HS) responded to treat- drogenism ment with the potent antiandrogen cyproterone acetate. They suggested that the disease could Q Sex hormones may affect the course of be androgen-dependent [8]. This hypothesis HS indirectly through, for example, was also upheld by occasional reports of women their effects on inflammation with HS under antiandrogen therapy [18]. Actu- ally, the androgen dependence of HS (similarly Q The role of end-organ sensitivity to acne) is only poorly substantiated. cannot be excluded at the time of writing 12.2 Hyperandrogenism and the Skin Q The prevalence of polycystic ovary syndrome in HS has not been system- Androgen-dependent disorders encompass a atically investigated broad spectrum of overlapping entities that may be related in women to the clinical consequenc- es of the effects of androgens on target tissues and of associated endocrine and metabolic dys- functions, when present. #ONTENTS 12.1 Introduction ...........................95 12.2.1 Androgenization 12.2 Hyperandrogenism and the Skin .........95 12.2.1 Androgenization .......................95 One of the less sex-specific effects of androgens 12.2.2 Androgen Metabolism ..................96 12.2.3 Causes of Hyperandrogenism ...........96 is that on the skin and its appendages, and in particular their action on the pilosebaceous 12.3 Lack of Association between HS unit. Hirsutism is the major symptom of hyper- and Endocrinopathies ..................97 androgenism in women.
    [Show full text]
  • Back to Basics: Understanding Hidradenitis Suppurativa
    PRACTICE DEVELOPMENT Back to basics: understanding hidradenitis suppurativa KEY WORDS Hidradenitis Suppurativa (HS) is a chronic recurrent debilitating skin disease of the Dermatology hair follicle. It is a condition that has been overlooked in wound care publications, Fistulae with most articles found in dermatological journals. However, the condition affects Hidradenitis Suppurativa 1% of the population in Europe and produces painful nodules in one or more of Scarring Sinus tracts the apocrine-gland bearing aspects of the skin that can ulcerate and produce pain and a foul odour and can multiply and eventually develop sinus tracts and fistulae. HS is often misdiagnosed as alternative skin ulcerating conditions, leaving the individuals with many years of suffering from the physical symptoms and their psychological consequences. The disease often begins in puberty and burns out by middle age, leaving the individual with unsightly scarring. This article examines the pathophysiology, clinical presentations and comorbidities associated with the disease. The treatment options focus on controlling the comorbidities, moderating life-style behaviours and arresting the disease. The medical and surgical options are discussed along with their limitations. idrarenitis Suppurativa (HS) was first selection bias, however is thought to be 1% in described by the French surgeon Velpeau Europe (Gulliver et al, 2016; WUWHS, 2016). in 1839. The origin of the term HS comes Prevalence is rare in children and when HS does Hfrom the Greek hidros meaning sweat and aden occur in this population it is often associated with denoting glands (Ather et al, 2006). Initially it was hormonal disorders such as metabolic syndrome, thought to be due to infection of the sweat glands precocious puberty, adrenal hyperplasia and however it is now recognized as an acneform premature adrenarche (Vivar and Kruse, 2017).
    [Show full text]
  • Metformin for the Treatment of Hidradenitis Suppurativa: a Little Help Along the Way
    DOI: 10.1111/j.1468-3083.2012.04668.x JEADV ORIGINAL ARTICLE Metformin for the treatment of hidradenitis suppurativa: a little help along the way R. Verdolini,† N. Clayton,‡,* A. Smith,‡ N. Alwash,† B. Mannello§ †Department of Dermatology, Princess Alexandra Hospital NHS trust, Harlow, Essex, and ‡Department of Dermatology, The Royal London Hospital, London, UK §Mannello Statistics, Via Rodi, Ancona, Italy *Correspondence: N. Clayton. E-mail: [email protected]; [email protected] Abstract Background Despite recent insights into its aetiology, hidradenitis suppurativa (HS) remains an intractable and debilitating condition for its sufferers, affecting an estimated 2% of the population. It is characterized by chronic, relapsing abscesses, with accompanying fistula formation within the apocrine glandbearing skin, such as the axillae, ano-genital areas and breasts. Standard treatments remain ineffectual and the disease often runs a chronic relapsing course associated with significant psychosocial trauma for its sufferers. Objective To evaluate the clinical efficacy of Metformin in treating cases of HS which have not responded to standard therapies. Methods Twenty-five patients were treated with Metformin over a period of 24 weeks. Clinical severity of the disease was assessed at time 0, then after 12 weeks and finally after 24 weeks. Results were evaluated using Sartorius and DLQI scores. Results Eighteen patients clinically improved with a significant average reduction in their Sartorius score of 12.7 and number of monthly work days lost reduced from 1.5 to 0.4. Dermatology life quality index (DLQI) also showed a significant improvement in 16 cases, with a drop in DLQI score of 7.6.
    [Show full text]
  • Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review
    toxins Review Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review Emanuela Martina †, Federico Diotallevi †, Giulia Radi †, Anna Campanati * and Annamaria Offidani Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60020 Ancona, Italy; [email protected] (E.M.); [email protected] (F.D.); [email protected] (G.R.); annamaria.offi[email protected] (A.O.) * Correspondence: [email protected] † These authors equally contributed to the manuscript. Abstract: Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin.
    [Show full text]
  • Hidradenitis Suppurativa FOUR CORNERS of CARE
    THE www.thedermdigest.com Vol. 2, No. 3 | March 2021 Hidradenitis Suppurativa FOUR CORNERS OF CARE Topical CBD: Hope or Hype? The Dermatologist as PCP Ask the Experts Permit No. 129 No. Permit Your Most High-Impact Columbus, WI Columbus, PAID Cosmetic Innovations US Postage US Prsrt Mkt Prsrt EDUCATIONAL • INTERACTIVE • AUTHORITATIVE Say Hello again to Not Actual Size Most eligible commercially $ per prescription insured patients pay as little as 20at any pharmacy* * Certain restrictions apply. The LEO Pharma CONNECT program may reduce out-of-pocket expenses. Must be 12 years of age or older to be eligible, and a legal guardian over 18 years of age must redeem the card for patients aged 12 to 17. You are not eligible if you are enrolled or you participate in any state or federally funded health care program (eg, Medicare, Medicaid, etc). Full details of the LEO Pharma CONNECT program are available at www.FinaceaFoam.com/hcp or may be obtained by calling 1-877-678-7494 between 8:30 AM and 8:30 PM (Eastern), Monday through Friday. The LEO Pharma logo, LEO Pharma, and Finacea are registered trademarks of LEO Pharma A/S. www.FinaceaFoam.com ©2020 LEO Pharma Inc. All rights reserved. March 2020 MAT-32481 THE Contents www.thedermdigest.com Volume 2, Number 3 | March 2021 14 Cover Article You can help hidradenitis suppurativa patients achieve long-term control and avoid flares 2 20 Ted Talks Pediatrics Do you talk politics in your office? Combination therapy can produce good clearance of pediatric warts 6 Literature Lessons Research updates in rheumatologic diseases, psoriasis, hair and nails, contact dermatitis, acne, rosacea, and more continued on page 3 March 2021 | 1 Ted Talks “ In politics, stupidity is not a handicap.” —Attributed to Napoleon Bonaparte he year was 1960, in the middle of a highly conten- T tious presidential contest between John F.
    [Show full text]
  • Folliculitis Highlights Author: Indira Gowda (EM Resident Physician, Mount Sinai Hospital) • Definition: O Inflammation Of
    Folliculitis Highlights Author: Indira Gowda (EM Resident Physician, Mount Sinai Hospital) Definition: o Inflammation of the hair follicle caused by either chemical/physical irritation or viral/bacterial infection o Folliculitis is the smallest and most minor o Furuncles are larger, carbuncles larger than that, and boils even larger (3) Taken From: http://www.shorthillsderm .com/blog/wp- Common associations: content/uploads/2014/11/ o Diabetes, immunosuppression, shaving What-is-Folliculitis.jpg Diagnosis: o Based on appearance and history o Usually seen on scalp, face, legs, back, chest, axilla o Folliculitis is usually not tender compared to carbuncles and furuncles o If someone has had recent contact w/ hot tub or DM, consider pseudomonas as potential bacteria (3) o May see hyper- or hypopigmentation post infection Tx: o Warm compresses 3 times/day o Antibiotics as treatment of recurrent infections is controversial as increased antibiotic use may lead to increased resistance . Topical mupirocin for moderate folliculitis, more severe infections may require antibiotics . For tx of strep: dicloxacillin or cefadroxil; tx of strep infections helps to prevent PSGN but no effect on rheumatic fever (3) . For tx of pseudomonas: fluoroquinolones or carbapenems or other anti-pseudomonal options . For tx staph (particularly MRSA): 7-10 day course of Bactrim, clindamycin, doxycycline, vancomycin, linezolid,… other antibiotics reserved for more severe infections. (5) o Many people carry MRSA in their nares. Between 10-35% are persistent carriers and 20-75% intermittent carriers. (4) . Should we treat carriers? (Mashhood AA, 2006) recommends nasal Taken from http://riversideonline.com swab testing in all patients with recurrent “furunculosis” aka boils /source/images/image_po aka abscesses.
    [Show full text]
  • Understanding Hidradenitis Suppurativa (Hs)
    UNDERSTANDING HIDRADENITIS SUPPURATIVA (HS) Information to help you work with your doctor so you can better manage your HS WHAT’S INSIDE Hidradenitis suppurativa (HS) in brief . 4 HS – the facts . 5 Living with HS . 9 Coping with HS . 11 Tips and tricks for living with HS . 12 Addressing your thoughts and feelings . 14 Coping with stress . 16 Working with your health care team . 17 Symptom self-assessment questionnaire . 19 Useful online resources . 23 3 HIDRADENITIS SUPPURATIVA (HS) IN BRIEF You have been diagnosed with HS, a disease which is: PAINFUL PRORESSIVE INFLAMMATORY GETTING WORSE CAUSING OVER TIME SWELLING CHRONIC SYSTEMIC LASTING AFFECTING A LONG TIME THE WHOLE BODY HS is known to produce lesions in the skin that are inflamed (swollen), recurrent (reappearing after lesions disappear), and chronic (lasting a long period of time). HS can have both a physical and psychological impact. The resulting pain and affected areas of your skin can restrict movement and your ability to do day-to-day tasks. Because of the areas of the body affected and how unsightly, smelly, and uncomfortable or painful HS may be, it can also lead to negative feelings such as embarrassment, stress and low mood. While we understand this is how some people with HS may feel, it’s important to remember that HS is a medical condition — its development is not your fault. 4 It’s important to be able to manage the physical side of the condition while also trying to reduce any feelings of embarrassment you may feel. There is more information about addressing your thoughts and feelings on page 14.
    [Show full text]
  • RIPE for the PICKING Experts Profile the Future of Biologic Treatments
    RIPE FOR THE PICKING Experts profile the future of biologic treatments 22 DERMATOLOGY WORLD // September 2015 www.aad.org/dw BY VICTORIA HOUGHTON, ASSISTANT MANAGING EDITOR John Harris, MD, PhD, assistant professor of medicine at the University of Massachusetts in the division of dermatology — like many dermatologists — has watched the impressive evolution of treatments for psoriasis over the last decade with anticipation. “We initially had very broad immunosuppressants that were somewhat effective in some patients, but they also had significant side effects,” Dr. Harris said. However, “The onset of biologics and other targeted therapies has been incredible. They’ve revolutionized treatment for psoriasis.” However, while physicians are enthusiastic about the progress of these treatments for psoriasis, there is also hope that interest in developing these innovative therapies is increasingly shifting to other skin conditions. “Pharmaceutical companies have to start looking elsewhere, given how good current psoriasis therapies are,” Dr. Harris said. “The real room for growth is in other diseases.” As psoriasis has paved the way for an interest in developing biologic and other targeted treatments in skin conditions, physicians are anticipating a promising future for these treatments in the following conditions: Atopic dermatitis Hidradenitis suppurativa Chronic urticaria Vitiligo Dermatomyositis >> Alopecia areata DERMATOLOGY WORLD // September 2015 23 RIPE FOR THE PICKING Atopic dermatitis 133; 6:1626-34). The study showed that by blocking the According to Lawrence Eichenfield, MD, professor of immune pathways with CsA, the molecular abnormalities dermatology and pediatrics at the University of California, with AD skin barrier genes, such as filaggrin and loricrin, San Diego and chief of pediatric and adolescent dermatology normalized.
    [Show full text]
  • Hidradenitis Suppurativa Hidradenitis Suppurativa (HS) Is an Inflammatory Skin Disease That Many People Mistake for Acne Or Infectious Boils
    Dermatology Patient Education Hidradenitis Suppurativa Hidradenitis suppurativa (HS) is an inflammatory skin disease that many people mistake for acne or infectious boils. Another name for HS is acne inversa, which means acne that appears in the skin folds such as the underarms, groin, buttocks, and underneath the breasts. Unlike acne, many people have HS for life. Early diagnosis can help patients receive effective treatment options that will help control symptoms. WHAT DOES HS LOOK LIKE? HS typically looks like acne on a part of the body where you normally would not have acne, particularly on areas of the body where skin touches skin. You may notice: • Pimple-like bumps • Deep acne-like cysts and blackheads • Bumps with a hair coming out of them (folliculitis) • Boils • Scarring Hidradenitis Suppurativa If HS worsens, you may notice that your bumps grow larger, become painful, and feel hot and tender. If HS bumps break open or rupture, they can leak a blood-stained, foul-smelling pus. Once the bumps heal, deep scars can appear that look like tunnels under the skin. These scars can be painful and thicken. You may experience a limited range of motion in the area where the bumps appeared because of scarring and pain. HS is most common in the armpits and groin. It also forms on and under women’s breasts, on the buttocks, and around the anus. As it worsens, HS can appear on skin that receives a lot of friction such as around your waist, the inner thighs, and the back of your neck. It even develops behind the ears, on the scalp, and on the eyelids.
    [Show full text]
  • Common Infections of the Skin Candida of Nails How to Diagnose
    Candida of Nails • Occurs in persons who have hands in water • Green nails represent the co‐pathogen which is pseudomonas Common Infections of the Skin TREATMENT: • Fluconazole 150 mg qd x1 month PLUS Ciprofloxacin 500 bid x 2 weeks Toby Maurer, MD OR University of California, San Francisco Thymol 2‐4% soak 20 mins bid x 3 months and tobramycin or gentamycin ophthalmologic drops How to diagnose Onychomycosis • Not all dystrophic nails= onychomycosis • Topical treatment –use for the right type of • KOH‐difficult to do and operator dependent lesions • CULTURE is gold standard but takes 3 weeks to grow out. • Naftin gel for small superficial lesions • Now PCR‐used in Europe with high sensitivity and • Penlac (Ciclopirox 8%) reported to work 35‐ specificity 52% of the time • Cost effective and results in 24‐72 hours – cost: expensive 1 Right type of lesions for topicals • Lunula not affected • Griseofulvin‐least hepatotoxic but lower • Less than 5 nails affected efficacy‐ 250 mg bid x 12‐18 months • No thickening of nails • Fluconazole‐ 150 mg qweek for more than 6 • No separation of nail plate on sides months –July 2012 Dermat Tx Gupta AK et al • Itraconazole‐ can pulse it‐ 400 mg qd x 7 days q month x 4 months Terbinafine (Lamisil) • Still the leader of the pack‐most effective in BASELINE 1 YR 5 YR terms of INITIAL and LONG‐TERM cure rate. • DOSE: 250 mg qd Continuously x 3 months Terbinafine 77% 75% 50% for fingernails and x4 months for toenails Itraconazole 70% 50% 13% (July 2012) i.e. no pulsing Grispeg 41% Fluconazole ? ? ? 2 Liver toxicity What about laser? • Transaminase elevation 0.4% to 1% with • Photo‐ inactivation laser and destructive terbinafine and intraconazole laser • Transaminase elevation does not predict liver • 4 studies‐2 – no results; 2 show results but failure with recurrence.
    [Show full text]
  • Finasteride for the Treatment of Hidradenitis Suppurativa in Children and Adolescents
    OBSERVATION Finasteride for the Treatment of Hidradenitis Suppurativa in Children and Adolescents Harkamal Kaur Randhawa, MD; Jill Hamilton, MD; Elena Pope, MD Importance: Hidradenitis suppurativa (HS) is a chronic ity of disease flares with no significant adverse effects. debilitating cutaneous disease for which there is no uni- versally effective treatment. Patients typically present at Conclusions and Relevance: Finasteride is a thera- puberty with tender subcutaneous nodules that can prog- peutic option that provides benefit for pediatric patients ress to dermal abscess formation. Antiandrogens have been with HS. Further prospective data and randomized con- used in the treatment of HS, and studies have primarily trolled studies will provide helpful information in the man- focused on adult patients. agement of this disease. Observations: We present a case series of 3 pediatric JAMA Dermatol. 2013;149(6):732-735. patients with HS who were successfully treated with oral Published online March 20, 2013. finasteride, resulting in decreased frequency and sever- doi:10.1001/jamadermatol.2013.2874 IDRADENITIS SUPPURA- from that of cyproterone acetate, a previ- tiva (HS) is a chronic in- ously studied antiandrogen in patients flammatory disease that with HS. We outline findings in 3 cases primarily involves skin in presenting during childhood, all in pa- the axillae, groin, and tients who showed significant improve- Hanogenital regions, although disease may ment in disease activity with finasteride extend to the buttocks, chest, scalp, eye- treatment. lids, and retroauricular areas.1 Patients with HS develop exquisitely painful erythem- REPORT OF CASES atous subcutaneous nodules that may heal spontaneously or suppurate and coalesce to form dermal abscesses.
    [Show full text]